<DOC>
	<DOCNO>NCT00636467</DOCNO>
	<brief_summary>The purpose study evaluate quality criterion SLN detection technique breast cancer patient tumor size ( clinical measurement ) great 2 centimeter ( rate false negative , rate detection ) . Eligible patient register ( randomization ) . The estimated inclusion period approximately 24 month . The duration research 25 month ( 24 month patient inclusion + 1 month reception result ) . The maximum participation duration patient 1 month . The number patient require multicentric prospective study 240 ( 16 participate center ) .</brief_summary>
	<brief_title>Axillary Sentinel Lymph Node Detection Breast Cancers &gt; 2 cm</brief_title>
	<detailed_description>Axillary node extension one major prognostic factor breast cancer . Axillary dissection Berg level I II node validate method obtain information lymph node invasion , associate important morbidity . Sentinel lymph node assessment ( SLN ) develop select patient likely axillary node extension use technique less invasive conventional dissection . Axillary dissection restrict patient undetected metastatic SLN . SLN detection involve subareolar peri-tumoral injection lymphotropic contrast agent map regional lymphatic drainage pattern tumor . This technique allow optimization histopathological analysis : pathologist must analyze two node average ( instead 10-15 ) , allow examination numerous tissue section development specific technique immunohistochemistry . The principal indicator success technique detection rate , false negative rate number SLN sample . The assessment feasibility base concomitant histopathological analysis SLN complementary lymph node . There consensus literature SLN technique use tumor clinical size superior 2 cm diameter . The aim prospective , multicentric study evaluate performance SLN technique , term detection rate false negative rate , patient tumor great 2 cm ( clinical measurement ) . A homogeneous technique `` combined '' , colorimetric isotopic SLN detection subareolar peri-tumoral injection use . This consensus `` combine '' technique validate investigator . The histopathological procedure also homogeneous , validate within group pathologist Fédération Nationale de Centres de Lutte Contre le Cancer ( FNCLCC ) . Breast surgery either mastectomy conservative treatment . The primary objective study evaluate quality criterion SLN detection technique breast cancer patient tumor size ( clinical measurement ) great 2 centimeter ( rate false negative , rate detection ) . The secondary objective : - Evaluation number SLN sample per patient , - Lymphoscintigraphic evaluation pattern lymphatic drainage breast tumor &gt; 2 centimeter , - Precise histopathological description SLN sample axillary node level I II . Evaluation criterion : The primary criterion rate false negative , determine ratio number patient detect negative SLN total number positive non-sentinel node time axillary dissection level I II ( patient classify N+ accord TNM system ) . This rate determine calculation detection rate , determine ratio number patient evaluate total number patient . In agreement international recommendation , expect rate false negative &lt; 5 % detection rate &gt; 85 % . Secondary criterion include : - Total number sample SLN per patient , - Lymphoscintigraphy : detection SLN mean extra-axillary marking , - Histopathological result : - SLN : metastasis , capsular breach , micro metastasis , isolated cell , - Dissection : number positive node .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female , age ≥ 18 year Patient invasive unifocal breast cancer tumor size &gt; 2 cm initial examination ( clinical examination and/or image ) Preoperative histological diagnosis infiltrate mammary carcinoma No lymph node clinical examination No treatment cancer surgery Mandatory affiliation social security system Written , sign inform consent No invasive breast cancer Breast tumor = &lt; 2 cm Preoperative histological diagnosis infiltrate mammary carcinoma Multifocal breast cancer Inflammatory breast cancer Metastatic cancer History homolateral breast surgery History allergic disorder History homolateral breast cancer Difficult followup Pregnant lactate woman Previous inclusion trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Breast cancer ( tumor &gt; 2 cm )</keyword>
	<keyword>Detection</keyword>
	<keyword>Axillary sentinel lymph node</keyword>
</DOC>